



Australian Government
Department of Industry,
Innovation and Science

Business
Cooperative Research
Centres Programme

28 July 2016

An antibody based *in vitro* diagnostic for metastatic cancer

Parties: Chemocopeia Pty Ltd; Innoviron Pty Ltd; 360biolabs Pty Ltd; CSIRO

We are delighted to announce a successful bid in the first selection round of the Cooperative Research Centres Projects (CRC-P) stream of the CRC Programme. Chemocopeia, Innoviron, 360biolabs and CSIRO will collaborate to develop a novel *in vitro* diagnostic test for metastatic cancer.

CSIRO will utilise its platform technologies in antibody selection, optimisation, characterisation and production to develop a means of detecting Chemocopeia's new biomarker and Innoviron and 360biolabs (a joint initiative with the Burnet Institute) will optimise and validate an assay suitable for diagnostic applications.

360biolabs will provide training in assay design and optimisation both to Burnet Institute staff and students *via* workplace training programmes (*e.g.* from Monash University). 360biolabs operates NATA accredited (ISO / IEC 17025 and 15189) laboratory facilities and systems including PC-2, PC-3 and quarantine laboratories. The total project value is \$1,174,220 of which \$582,500 is the total grant amount. The parties thank the Department of Industry, Innovation and Science - CRC Programme for the support and are excited by the opportunity to translate our science into a diagnostic product for the management of metastatic cancer.



For more information please contact:

Dr John J. Deadman

Tel: +61 408 538 488

jjdeadman@chemocopeia.com.au

[Chemocopeia Pty Ltd](#)

Dr Simon P. Tucker

Tel: +61 419 563 259

s.tucker@360biolabs.com

[360biolabs Pty Ltd](#)